Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 297-308

  Rolain, Jean Marc ^a   Colson, Philippe ^a   Raoult, Didier ^a  

^a CNRS   (France)

Author keywords

Alkalinisation; Chloroquine; HIV; Hydroxychloroquine; Lysosomotropic agents; Q fever; Whipple's disease

Indexed keywords

ANTIRETROVIRUS AGENT; CHLOROQUINE; DIDANOSINE; DOXYCYCLINE; HYDROXYCHLOROQUINE; HYDROXYL GROUP; NEVIRAPINE; PROTEINASE INHIBITOR; QUINOLONE; TETRACYCLINE; ZIDOVUDINE;

ADD ON THERAPY; ALKALINIZATION; ANTIMALARIAL ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL GROWTH; CELL PH; CLINICAL TRIAL; CORONAVIRUS; COXIELLA BURNETII; DRUG WITHDRAWAL; ENDOCARDITIS; FRANCISELLA TULARENSIS; FUNGUS GROWTH; GLYCOSYLATION; GROWTH INHIBITION; HEPATITIS B; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE LIPODYSTROPHY; MACULAR RETINOPATHY; MALARIA; MYCOBACTERIUM TUBERCULOSIS; ORTHOMYXOVIRUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; Q FEVER; RHEUMATIC DISEASE; SEVERE ACUTE RESPIRATORY SYNDROME; SHORT SURVEY; TREATMENT DURATION; TROPHERYMA WHIPPELII;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CHLOROQUINE; HUMANS; HYDROXYCHLOROQUINE; MYCOSES; VIRUS DISEASES;

EID: 34548460117     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.015     Document Type: Short Survey

References (130)

1. Wellems T.E., and Plowe C.V. Chloroquine-resistant malaria. J Infect Dis 184 (2001) 770-776
2. Savarino A., Lucia M.B., Rastrelli E., et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35 (2004) 223-232
3. O'Neill P.M., Bray P.G., Hawley S.R., Ward S.A., and Park B.K. 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol Ther 77 (1998) 29-58
4. Hackstadt T., and Williams J.C. Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci USA 78 (1981) 3240-3244
5. Maurin M., Benoliel A.M., Bongrand P., and Raoult D. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 166 (1992) 1097-1102
6. Raoult D., Houpikian P., Tissot Dupont H., Riss J.M., Arditi-Djiane J., and Brouqui P. Treatment of Q fever endocarditis: comparison of two regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 159 (1999) 167-173
7. Ghigo E., Capo C., Aurouze M., et al. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect Immun 70 (2002) 1501-1506
8. Boulos A., Rolain J.M., and Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 48 (2004) 747-752
9. Maurin M., and Raoult D. Optimum treatment of intracellular infection. Drugs 52 (1996) 45-59
10. Maurin M., and Raoult D. Intracellular organisms. Int J Antimicrob Agents 9 (1997) 61-70
11. Byrd T.F., and Horwitz M.A. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 88 (1991) 351-357
12. Fortier A.H., Leiby D.A., Narayanan R.B., et al. Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun 63 (1995) 1478-1483
13. Raoult D., Drancourt M., and Vestris G. Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 34 (1990) 1512-1514
14. Crowle A.J., and May M.H. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob Agents Chemother 34 (1990) 2217-2222
15. Boelaert J.R., Appelberg R., Gomes M.S., et al. Experimental results on chloroquine and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr 26 (2001) 300-301
16. Horowitz H., and Carbonaro C.A. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 166 (1992) 1462-1464
17. Wiseman D. The effect of pH on the inhibitory activity of chloroquine against Escherichia coli. J Pharm Pharmacol 24 Suppl. (1972) 162P
18. Artenstein A.W., Opal S.M., Cristofaro P., et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J Infect Dis 190 (2004) 1655-1660
19. Smith K.T., and Dawes I.W. The preferential inhibition of Bacillus subtilis spore outgrowth by chloroquine. Arch Microbiol 152 (1989) 251-257
20. Brorson O., and Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine. Int Microbiol 5 (2002) 25-31
21. Detilleux P.G., Deyoe B.L., and Cheville N.F. Effect of endocytic and metabolic inhibitors on the internalization and intracellular growth of Brucella abortus in Vero cells. Am J Vet Res 52 (1991) 1658-1664
22. Nguyen H.A., Grellet J., Paillard D., Dubois V., Quentin C., and Saux M.C. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. J Antimicrob Chemother 57 (2006) 883-890
23. Prada-Delgado A., Carrasco-Marin E., Pena-Macarro C., et al. Inhibition of Rab5a exchange activity is a key step for Listeria monocytogenes survival. Traffic 6 (2005) 252-265
24. Newman S.L., Gootee L., Brunner G., and Deepe Jr. G.S. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest 93 (1994) 1422-1429
25. Levitz S.M., Harrison T.S., Tabuni A., and Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest 100 (1997) 1640-1646
26. Dias-Melicio FPetruzzielloL.A., Moreira A.P., Calvi S.A., and Soares A.M. Chloroquine inhibits Paracoccidioides brasiliensis survival within human monocytes by limiting the availability of intracellular iron. Microbiol Immunol 50 (2006) 307-314
27. Taramelli D., Tognazioli C., Ravagnani F., Leopardi O., Giannulis G., and Boelaert J.R. Inhibition of intramacrophage growth of Penicillium marneffei by 4-aminoquinolines. Antimicrob Agents Chemother 45 (2001) 1450-1455
28. Jahn B., Langfelder K., Schneider U., Schindel C., and Brakhage A.A. PKSP-dependent reduction of phagolysosome fusion and intracellular kill of Aspergillus fumigatus conidia by human monocyte-derived macrophages. Cell Microbiol 4 (2002) 793-803
29. Sperber K., Kalb T.H., Stecher V.J., Banerjee R., and Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 9 (1993) 91-98
30. Ferreira D.F., Santo M.P., Rebello M.A., and Rebello M.C. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J. Med. Microbiol. 49 4 (2000) 313-318
31. Pardridge W.M., Yang J., and Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett 64 (1998) 45-47
32. Chiang G., Sassaroli M., Louie M., Chen H., Stecher V.J., and Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 18 (1996) 1080-1092
33. Vincent M.J., Bergeron E., Benjannet S., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2 (2005) 69
34. Keyaerts E., Vijgen L., Maes P., Neyts J., and Van R.M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323 (2004) 264-268
35. Shibata M., Aoki H., Tsurumi T., et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 64 (1983) 1149-1156
36. Savarino A., Di T.L., Donatelli I., Cauda R., and Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6 (2006) 67-69
37. Miller D.K., and Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci USA 78 (1981) 3605-3609
38. Ooi E.E., Chew J.S., Loh J.P., and Chua R.C. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 3 (2006) 39
39. Randolph V.B., Winkler G., and Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174 (1990) 450-458
40. Petruzziello R., Orsi N., Macchia S., Rieti S., Frey T.K., and Mastromarino P. Pathway of rubella virus infectious entry into Vero cells. J Gen Virol 77 Pt 2 (1996) 303-308
41. Nakhasi H.L., Zheng D., Callahan L., Dave J.R., and Liu T.Y. Rubella virus: mechanism of attenuation in the vaccine strain (HPV77). Virus Res 13 3 (1989) 231-243
42. Bishop N.E. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 41 (1998) 261-271
43. Offensperger W.B., Offensperger S., Walter E., Blum H.E., and Gerok W. Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology 183 (1991) 415-418
44. Civitico G., Wang Y.Y., Luscombe C., et al. Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 31 (1990) 90-97
45. Blanchard E., Belouzard S., Goueslain L., et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80 (2006) 6964-6972
46. Glushakova S.E., and Lukashevich I.S. Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch Virol 104 (1989) 157-161
47. Borrow P., and Oldstone M.B. Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology 198 1 (1994) 1-9
48. Tsiang H., and Superti F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells Brief report. Arch Virol 81 (1984) 377-382
49. Pontesilli O., Carotenuto P., Levin M.J., Suez D., and Hayward A.R. Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes. Clin Exp Immunol 70 (1987) 127-135
50. Lindemans C.A., Coffer P.J., Schellens I.M., de Graaff P.M., Kimpen J.L., and Koenderman L. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-κB-dependent mechanism. J Immunol 176 (2006) 5529-5537
51. Cassell S., Edwards J., and Brown D.T. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 52 (1984) 857-864
52. Singh A.K., Sidhu G.S., Friedman R.M., and Maheshwari R.K. Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine. J Interferon Cytokine Res 16 (1996) 725-731
53. Koyama A.H., and Uchida T. Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine. Virology 138 2 (1984) 332-335
54. Miller N., and Hutt-Fletcher L.M. Epstein-Barr virus enters B cells and epithelial cells by different routes. J Virol 66 (1992) 3409-3414
55. Zeichhardt H., Wetz K., Willingmann P., and Habermehl K.O. Entry of poliovirus type 1 and Mouse Elberfeld (ME) virus into HEp-2 cells: receptor-mediated endocytosis and endosomal or lysosomal uncoating. J Gen Virol 66 (1985) 483-492
56. Kronenberger P., Vrijsen R., and Boeye A. Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol 65 (1991) 7008-7011
57. Madshus I.H., Olsnes S., and Sandvig K. Mechanism of entry into the cytosol of poliovirus type 1: requirement for low pH. J Cell Biol 98 4 (1984) 1194-1200
58. Yoshida T., Takao S., Kiyotani K., and Sakaguchi T. Endoproteolytic activation of Newcastle disease virus fusion proteins requires an intracellular acidic environment. Virology 170 (1989) 571-574
59. Gonzalez-Dunia D., Cubitt B., and de la Torre J.C. Mechanism of Borna disease virus entry into cells. J Virol 72 (1998) 783-788
60. Miller D.K., and Lenard J. Inhibition of vesicular stomatitis virus infection by spike glycoprotein. Evidence for an intracellular, G protein-requiring step. J Cell Biol 84 2 (1980) 430-437
61. Fredericksen B.L., and Whitt M.A. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness. Virology 240 (1998) 349-358
62. Dille B.J., and Johnson T.C. Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine. J Gen Virol 62 (1982) 91-103
63. Janeczko R.A., Rodriguez J.F., and Esteban M. Studies on the mechanism of entry of vaccinia virus in animal cells. Arch Virol 92 (1987) 135-150
64. Pazmino N.H., Yuhas J.M., and Tennant R.W. Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine. Int J Cancer 14 (1974) 379-385
65. Carrillo E.C., Giachetti C., and Campos R. Early steps in FMDV replication: further analysis on the effects of chloroquine. Virology 147 (1985) 118-125
66. Ferreira D.F., Santo M.P., Rebello M.A., and Rebello M.C. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J Med Microbiol 49 (2000) 313-318
67. Stuart A.D., and Brown T.D. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J Virol 80 (2006) 7500-7509
68. Geraldes A., and Valdeira M.L. Effect of chloroquine on African swine fever virus infection. J Gen Virol 66 Pt 5 (1985) 1145-1148
69. Mager A., Masengo R., Mammerickx M., and Letesson J.J. T cell proliferative response to bovine leukaemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values. J Gen Virol 75 (1994) 2223-2231
70. Basak S., and Turner H. Infectious entry pathway for canine parvovirus. Virology 186 (1992) 368-376
71. Ros C., Burckhardt C.J., and Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol 76 24 (2002) 12634-12645
72. Hackstadt T., and Williams J.C. pH dependence of the Coxiella burnetii glutamate transport system. J Bacteriol 154 (1983) 598-603
73. Mege J.L., Maurin M., Capo C., and Raoult D. Coxiella burnetii: the 'query' fever bacterium. A model of immune subversion by a strictly intracellular microorganism. FEMS Microbiol Rev 19 (1997) 209-217
74. Maurin M., and Raoult D. Q fever. Clin Microbiol Rev 12 (1999) 518-553
75. Fenollar F., Fournier P.E., Carrieri M.P., Habib G., Messana T., and Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 33 (2001) 312-316
76. Madariaga M.G., Pulvirenti J., Sekosan M., Paddock C.D., and Zaki S.R. Q fever endocarditis in HIV-infected patient. Emerg Infect Dis 10 (2004) 501-504
77. Senn L., Franciolli M., Raoult D., et al. Coxiella burnetii vascular graft infection. BMC Infect Dis 5 (2005) 109
78. Fenollar F., Thuny F., Xeridat B., Lepidi H., and Raoult D. Endocarditis after acute Q fever in patients with previously undiagnosed valvulopathies. Clin Infect Dis 42 (2006) 818-821
79. Landais C., Fenollar F., Thuny F., and Raoult D. From acute Q fever to endocarditis: serological follow-up strategy. Clin Infect Dis 44 (2007) 1337-1340
80. Landais C., Fenollar F., Constantin A., et al. Q fever osteoarticular infection: four new cases and a review of the literature. Eur J Clin Microbiol Infect Dis 26 (2007) 341-347
81. Raoult D., Birg M.L., La Scola B., et al. Cultivation of the bacillus of Whipple's disease. New Engl J Med 342 (2000) 620-625
82. Fenollar F., Puechal X., and Raoult D. Whipple's disease. New Engl J Med 256 (2007) 55-66
83. Rogers D.E., and Tompsett R. The survival of staphylococci within human leukocytes. J Exp Med 95 (1952) 209-230
84. Kapral F.A., and Shayegani M.G. Intracellular survival of staphylococci. J Exp Med 110 (1959) 123
85. Craven N., Williams M.R., Field T.R., Bunch K.J., Mayer S.J., and Bourne S.J. The influence of extracellular and phagolysosomal pH changes on the bactericidal activity of bovine neutrophils against Staphylococcus aureus. Vet Immunol Immunopathol 13 (1986) 97-110
86. Styrt B., and Klempner M.S. Modification of interactions between neutrophils and staphylococci by lysosomotropic week bases. Infect Immun 50 (1985) 415-419
87. Yancey R.J., Sanchez M.S., and Ford C.W. Activity of antibiotics against Staphylococcus aureus within polymorphonuclear neutrophils. Eur J Clin Microbiol Infect Dis 10 (1991) 107-113
88. Lam C., and Mathison G.E. Effect of low intraphagolysosomal pH on antimicrobial activity of antibiotics against ingested staphylococci. J Med Microbiol 16 (1983) 309-316
89. Maurin M., and Raoult D. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J Infect Dis 169 (1994) 330-336
90. Nguyen H.A., Grellet J., Dubois V., Saux M.C., and Quentin C. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus. J Antimicrob Chemother 59 (2007) 755-758
91. Sanchez M.S., Ford C.W., and Yancey Jr. R.J. Evaluation of antibiotic effectiveness against Staphylococcus aureus surviving within the bovine mammary gland macrophage. J Antimicrob Chemother 21 (1988) 773-786
92. Tulkens P.M. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 10 (1991) 100-106
93. Mandell G.L., and Vest T.K. Killing of intraleukocytic Staphylococcus aureus by rifampin: in vitro and in vivo studies. J Infect Dis 125 (1972) 486-490
94. Stout J.E., and Yu V.L. Legionellosis. N Engl J Med 337 (1997) 682-687
95. Weber S.M., Levitz S.M., and Harrison T.S. Chloroquine and the fungal phagosome. Curr Opin Microbiol 3 (2000) 349-353
96. Harrison T.S., Chen J., Simons E., and Levitz S.M. Determination of the pH of the Cryptococcus neoformans vacuole. Med Mycol 40 (2002) 329-332
97. Eissenberg L.G., Goldman W.E., and Schlesinger P.H. Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med 177 (1995) 1605-1611
98. Strasser J.E., Newman S.L., Ciraolo G.M., Morris R.E., Howell M.L., and Dean G.E. Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. J Immunol 162 (1999) 6148-6154
99. Schafer M.P., and Dean G.E. Cloning and sequence analysis of an H(+)-ATPase-encoding gene from the human dimorphic pathogen Histoplasma capsulatum. Gene 136 (1993) 295-300
100. Levitz S.M., Nong S.H., Seetoo K.F., Harrison T.S., Speizer R.A., and Simons E.R. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 67 (1999) 885-890
101. Sieczkarski S.B., and Whittaker G.R. Dissecting virus entry via endocytosis. J Gen Virol 83 (2002) 1535-1545
102. Naarding M.A., Baan E., Pollakis G., and Paxton W.A. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology 4 (2007) 6
103. Kwiek J.J., Haystead T.A., and Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 43 (2004) 4538-4547
104. Ducharme J., and Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31 (1996) 257-274
105. Boelaert J.R., Sperber K., and Piette J. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea. Biochem Pharmacol 61 (2001) 1531-1535
106. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De C.E., and Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9 (2004) 57-65
107. Sperber K., Louie M., Kraus T., et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 17 (1995) 622-636
108. Sperber K., Chiang G., Chen H., et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 19 (1997) 913-923
109. Paton N.I., Aboulhab J., and Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet 359 (2002) 1667-1668
110. Paton N.I., and Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med 6 (2005) 13-20
111. Joshi S.R., Butala N., Patwardhan M.R., Daver N.G., and Kelkar D. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. J Assoc Physicians India 52 (2004) 597-598
112. Engchanil C., Kosalaraksa P., Lumbiganon P., et al. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children. J Med Assoc Thai 89 (2006) 1229-1236
113. Kourtis A.P., Lee F.K., Abrams E.J., Jamieson D.J., and Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 6 (2006) 726-732
114. Savarino A., Boelaert J.R., Cassone A., Majori G., and Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 3 (2003) 722-727
115. Malaty L.I., and Kuper J.J. Drug interactions of HIV protease inhibitors. Drug Saf 20 2 (1999) 147-169
116. Projean D., Baune B., Farinotti R., et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31 (2003) 748-754
117. Li W., Moore M.J., Vasilieva N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
118. Gallagher T.M., Escarmis C., and Buchmeier M.J. Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J Virol 65 (1991) 1916-1928
119. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., and Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 101 (2004) 4240-4245
120. Yang Z.Y., Huang Y., Ganesh L., et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78 (2004) 5642-5650
121. Biot C., Daher W., Chavain N., et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 49 (2006) 2845-2849
122. Yoshimura A., Kuroda K., Kawasaki K., Yamashina S., Maeda T., and Ohnishi S. Infectious cell entry mechanism of influenza virus. J Virol 43 (1982) 284-293
123. Hirschman S.Z., and Garfinkel E. Inhibition of hepatitis B DNA polymerase by intercalating agents. Nature 271 (1978) 681-683
124. Hagelstein J., Fathinejad F., Stremmel W., and Galle P.R. pH-independent uptake of hepatitis B virus in primary human hepatocytes. Virology 229 (1997) 292-294
125. Kouroumalis E.A., and Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore 15 (1986) 149-152
126. Accapezzato D., Visco V., Francavilla V., et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med 202 (2005) 817-828
127. Rolain J.M., Mallet M.N., and Raoult D. Correlation between serum levels of doxycycline and serology evolution in patients treated for Coxiella burnetii endocarditis. J Infect Dis 9 (2003) 1322-1325
128. Rolain J.M., Boulos A., Mallet M.N., and Raoult D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 49 (2005) 2673-2676
129. Klinger G., Morad Y., Westall C.A., et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358 (2001) 813-814
130. Bernstein H.N. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 75 (1983) 25-34